Diamond Hill Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-117,817
| Closed | -$5.42M | – | 143 |
|
|
2020
Q4 | $5.42M | Sell |
117,817
-28,378
| -19% | -$1.3M | 0.03% | 126 |
|
|
2020
Q3 | $6.88M | Buy |
146,195
+1,422
| +1% | +$71.2K | 0.04% | 121 |
|
|
2020
Q2 | $7.38M | Sell |
144,773
-1,069
| -0.7% | -$54.8K | 0.04% | 120 |
|
|
2020
Q1 | $6.91M | Sell |
145,842
-85,163
| -37% | -$4.54M | 0.05% | 119 |
|
|
2019
Q4 | $13.6M | Sell |
231,005
-111,725
| -33% | -$6.21M | 0.07% | 111 |
|
|
2019
Q3 | $18.3M | Sell |
342,730
-14,776
| -4% | -$760K | 0.1% | 111 |
|
|
2019
Q2 | $17.9M | Sell |
357,506
-40,833
| -10% | -$2.05M | 0.1% | 111 |
|
|
2019
Q1 | $20.8M | Sell |
398,339
-30,730
| -7% | -$1.54M | 0.11% | 108 |
|
|
2018
Q4 | $20.5M | Buy |
429,069
+85,646
| +25% | +$4.22M | 0.12% | 113 |
|
|
2018
Q3 | $17.2M | Buy |
343,423
+196,439
| +134% | +$9.98M | 0.09% | 113 |
|
|
2018
Q2 | $7.41M | Sell |
146,984
-4,320
| -3% | -$218K | 0.04% | 130 |
|
|
2018
Q1 | $7.39M | Sell |
151,304
-6,874
| -4% | -$320K | 0.04% | 129 |
|
|
2017
Q4 | $7.01M | Buy |
158,178
+2,992
| +2% | +$138K | 0.04% | 130 |
|
|
2017
Q3 | $7.88M | Buy |
155,186
+3,144
| +2% | +$160K | 0.04% | 131 |
|
|
2017
Q2 | $8.2M | Hold |
152,042
| – | – | 0.04% | 132 |
|
|
2017
Q1 | $8.01M | Buy |
152,042
+30,996
| +26% | +$1.57M | 0.04% | 128 |
|
|
2016
Q4 | $5.83M | Hold |
121,046
| – | – | 0.03% | 139 |
|
|
2016
Q3 | $6.53M | Hold |
121,046
| – | – | 0.04% | 135 |
|
|
2016
Q2 | $6.56M | Hold |
121,046
| – | – | 0.04% | 135 |
|
|
2016
Q1 | $6.13M | Sell |
121,046
-6,979
| -5% | -$348K | 0.04% | 137 |
|
|
2015
Q4 | $6.46M | Sell |
128,025
-7,473
| -6% | -$381K | 0.04% | 138 |
|
|
2015
Q3 | $6.51M | Hold |
135,498
| – | – | 0.05% | 135 |
|
|
2015
Q2 | $7.05M | Buy |
135,498
+60,476
| +81% | +$3.41M | 0.05% | 131 |
|
|
2015
Q1 | $4.33M | Buy |
75,022
+31,788
| +74% | +$1.82M | 0.03% | 131 |
|
|
2014
Q4 | $2.31M | Buy |
43,234
+31,312
| +263% | +$1.75M | 0.02% | 134 |
|
|
2014
Q3 | $685K | Sell |
11,922
-139,791
| -92% | -$8.57M | 0.01% | 131 |
|
|
2014
Q2 | $10.1M | Sell |
151,713
-1,074
| -0.7% | -$72.7K | 0.08% | 122 |
|
|
2014
Q1 | $10.2M | Buy |
152,787
+143,538
| +1,552% | +$9.7M | 0.09% | 116 |
|
|
2013
Q4 | $617K | Hold |
9,249
| – | – | 0.01% | 134 |
|
|
2013
Q3 | $580K | Buy |
9,249
+1,600
| +21% | +$103K | 0.01% | 133 |
|
|
2013
Q2 | $478K | Buy |
+7,649
| New | +$485K | 0.01% | 139 |
|
Other funds holding GSK
BCIM
Diamond Hill Capital Management's GSK Position: Q1 2021 in Review
Diamond Hill Capital Management sold out of GSK (GSK) in Q1 2021, closing a stake of 117,817 shares — an estimated $5.42M sold.
Diamond Hill Capital Management first reported a position in GSK in Q2 2013 and held it in 31 quarters. The position peaked at $20.8M in Q1 2019. 774 funds tracked by Wall St. Rank hold GSK as of Q1 2021.
- Diamond Hill Capital Management reported no remaining GSK position as of Q1 2021 after selling out during the quarter.
- Diamond Hill Capital Management sold 117,817 GSK shares in Q1 2021, an estimated $5.42M.
- Diamond Hill Capital Management first reported a position in GSK in Q2 2013 and held it in 31 quarters.
- Diamond Hill Capital Management's GSK position peaked at $20.8M in Q1 2019.
- 774 funds tracked by Wall St. Rank held GSK as of Q1 2021.
Based on Diamond Hill Capital Management's 13F filing for Q1 2021, filed 4 May 2021.